



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Van Gilst et al.

Serial No.: 10/500,913

Filed: November 29, 2004

For: USE OF ERYTHROPOIETIN FOR
THE PREVENTIVE OR CURATIVE
TREATMENT OF CARDIAC FAILURE

Confirmation No.: 7130

Examiner: To be assigned

Group Art Unit: 1615

Attorney Docket No.: 2578-6485US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 9, 2006
Date

A. Blackburn
Signature

Aubry Blackburn
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record.

Copies of the references marked with a pound sign (#) are not provided since they were cited in the International Search Report, and as such, should have been provided by the WIPO under the exchange program. The references are as follows:

Other Documents

#SILVERBERG et al., "The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations," Journal of the American College of Cardiology, June 2000, pp. 1737-1744, Vol. 35, No. 7.

#MANCINI et al., "Erythropoietin improves exercise capacity in patients with heart failure," Circulation, 23 October 2001, pp. II.428, Vol. 104, No. 17 Supplement.

#AKIMOTO et al., "Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway," Kidney International, July 2000, pp. 269-282, Vol. 58, No. 1.

#WESTENFELDER et al., "Anti-apoptotic, mitogenic and motogenic actions of erythropoietin on tubular cells protect renal function and accerlerate recovery from ischemic acute renal failure in rats," Journal of Investigative Medicine, January 2001, pp. 59a, Vol. 49, No. 1.

#ARCASOY et al., "Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing," Blood, 16 November 2001, pp. 822a-823a, Vol. 98, No. 11, Part 1.

#KRAUSE et al., "Recombinant human erythropoietin stimulates angiogenesis in a novel in vitro assay of human myocardial tissue," Journal of the American College of Cardiology, February 2001, pp. 236a, Vol. 37, No. 2, Supplement A.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.:	2183-6629US
Serial No.:	10/946,329
Filed:	9/20/2004
Title:	USE OF ANGIOTENSIN-(1-7) FOR PREVENTING AND/OR REDUCING THE FORMATION OF NEOINTIMA



Serial No.: 10/500,913

Attorney Docket No.: 2183-6659US
Serial No.: 10/952,385
Filed: 9/28/2004
Title: USE OF ANGIOTENSIN 1-7 FOR ENHANCING CARDIAC
FUNCTION
Attorney Docket No.: 2578-5447.1US
Serial No.: 11/039,767
Filed: 1/18/2005
Title: RECOMBINANT PRODUCTION OF MIXTURES OF
ANTIBODIES

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: May 9, 2006
ACT/alb
Enclosures: Form PTO/SB/08



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/500,913
Filing Date	November 29, 2004
First Named Inventor	Van Gilst et al.
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	2578-6485UIS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SILVERBERG et al., "The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations," Journal of the American College of Cardiology, June 2000, pp. 1737-1744, Vol. 35, No. 7.	
		MANCINI et al., "Erythropoietin improves exercise capacity in patients with heart failure," Circulation, 23 October 2001, pp. II.428, Vol. 104, No. 17 Supplement.	
		AKIMOTO et al., "Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway," Kidney International, July 2000, pp. 269-282, Vol. 58, No. 1.	
		WESTENFELDER et al., "Anti-apoptotic, mitogenic and motogenic actions of erythropoietin on tubular cells protect renal function and accelerate recovery from ischemic acute renal failure in rats," Journal of Investigative Medicine, January 2001, pp. 59a, Vol. 49, No. 1.	
		ARCASOY et al., "Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing," Blood, 16 November 2001, pp. 822a-823a, Vol. 98, No. 11, Part 1.	
		KRAUSE et al., "Recombinant human erythropoietin stimulates angiogenesis in a novel in vitro assay of human myocardial tissue," Journal of the American College of Cardiology, February 2001, pp. 236a, Vol. 37, No. 2, Supplement A.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.